Clinical significance of heparin-binding epidermal growth factor-like growth factor and A disintegrin and metalloprotease 17 expression in human ovarian cancer

Yoshihiro Tanaka, Shingo Miyamoto, Satoshi O. Suzuki, Eiji Oki, Hiroshi Yagi, Kenzo Sonoda, Ayano Yamazaki, Hiroto Mizushima, Yoshihiko Maehara, Eisuke Mekada, Hitoo Nakano

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Purpose: Lysophosphatidic acid, which is enriched in the peritoneal fluid of ovarian cancer patients, plays a key role in the progression of ovarian cancer. Lysophosphatidic acid can generate epidermal growth factor receptor (EGFR) signal transactivation involving processing of EGFR ligands by ADAM (a disintegrin and metalloprotease) family metalloproteases, We aimed to investigate the clinical significance of EGFR ligands and ADAM family in the lysophosphatidic acid - induced pathogenesis of ovarian cancer. Experimental Design: We examined the expression of EGFR ligands and ADAM family members in 108 patients with normal ovaries or ovarian cancer, using real-time PCR, immunohistochemistry, and in situ hybridization, and analyzed the clinical roles of these molecules. Statistical analyses of these data were done using the Mann-Whitney test, Kaplan-Meier method, or Spearman's correlation analysis. Results: Large differences in expression were found for heparin-binding EGF-like growth factor (HB-EGF) and other EGFR ligands and for ADAM 17 and other ADAM family members. HB-EGF expression was significantly increased in advanced ovarian cancer compared with that in normal ovaries (P < 0.01). HB-EGF expression was significantly associated with the clinical outcome (P < 0.01). ADAM 17 expression was significantly enhanced in both early and advanced ovarian cancer compared with that in normal ovaries (both P < 0.01), although it had no clinical significance in the progression-free survival. HB-EGF expression was significantly correlated with ADAM 17 expression (γ = 0.437, P < 0.01). Conclusions: Our findings suggest that HB-EGF and ADAM 17 contribute to the progression of ovarian cancer and that HB-EGF plays a pivotal role in the aggressive behavior of a tumor in ovarian cancer.

Original languageEnglish
Pages (from-to)4783-4792
Number of pages10
JournalClinical Cancer Research
Volume11
Issue number13
DOIs
Publication statusPublished - Jul 1 2005

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical significance of heparin-binding epidermal growth factor-like growth factor and A disintegrin and metalloprotease 17 expression in human ovarian cancer'. Together they form a unique fingerprint.

  • Cite this